BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $20
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
Verastem Exercises Early Option To License From GenFleet VS-7375 - Quick Facts
Express News | Verastem Inc - to File U.S. Ind Application for Vs-7375 in Q1 2025
Express News | Verastem Oncology Exercises Option Early to License Vs-7375, an Oral Kras G12D (on/off) Inhibitor, From Genfleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
IPO Preview | After two and a half years of cumulative losses of 1.2 billion, under heavy debt pressure, Jingfang Pharmaceutical "injured" ventures into the Hong Kong Stock Exchange.
Jingfang Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}